Claus Jorgensen is a team leader at The Institute of Cancer Research, London UK. The main objective of the Jorgensen lab is to identify and dissect signalling aberrations in the development and progression of tumours. In particular, the Jorgensen lab focuses on the use and application of quantitative proteomics in combination with functional validation.